Calgary, Alberta–(Newsfile Corp. – September 1, 2022) – NurExone Biologic Inc. (TSXV:NRX) (formerly, EnerSpar Corp. or “EnerSpar”) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, announced today that it agrees to offer 170,195 common shares of the Company at a deemed price

https://www.entrepreneur.com/en-au/news-and-trends/israeli-companies-are-leading-the-global-biotechIn an attempt to become self-reliant, Israel invested in infrastructure, education, and technology to empower innovative leaders and field experts to lead the charge in their respective industries-charge/434706  read more

Tel Aviv, Israel, July 18, 2022 (GLOBE NEWSWIRE) — Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, announced today that Polyrizon Ltd. (“Polyrizon”), an Israeli biotech company that specializes in innovative intranasal products in which Medigus owns 37.03%,

Calgary, Alberta–(Newsfile Corp. – July 25, 2022) – NurExone Biologic Inc. (TSXV: NRX) (“NurExone” or the “Company”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other Central Nervous System (“CNS”) indications, is pleased to announce that it will showcase a poster presentation at the

Israeli biotech Polyrizon is collaborating with NurExone Biologic for intranasal administration of a therapy for spinal cord injuries (SCI). Under the agreement, Polyrizon — in which Medigus (NASDAQ:MDGS) owns a 37.03% stake — will use its Trap and Target platform to develop formulations, conduct analytical development and produce technical batches of a